Effects of raloxifene on breast cancer cell migration and invasion through the actin cytoskeleton

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 8 B, 2009, Pages 2396-2407

  Flamini, Marina Ines ^a   Fu, Xiao Dong ^a   Sanchez, Angel Matias ^a   Giretti, Maria Silvia ^a   Garibaldi, Silvia ^a   Goglia, Lorenzo ^a   Pisaneschi, Silvia ^a   Tosi, Veronica ^a   Genazzani, Andrea Riccardo ^a   Simoncini, Tommaso ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Breast cancer; Invasion; Migration; Moesin; Oestrogen; Raloxifene

Indexed keywords

ACTIN; RALOXIFENE;

ARTICLE; BREAST TUMOR; CANCER INVASION; CYTOSKELETON; FEMALE; HUMAN; METABOLISM; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ACTINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOSKELETON; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RALOXIFENE;

EID: 72949117024     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00505.x     Document Type: Article

References (25)

1. Simoncini T, Genazzani AR. Timing is everything. Gynecol Endocrinol. 2007 23 : 1 4.
2. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med. 2003 348 : 618 629.
3. Francucci CM, Romagni P, Boscaro M. Raloxifene: bone and cardiovascular effects. J Endocrinol Invest. 2005 28 : 85 9.
4. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002 287 : 847 857.
5. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006 295 : 2727 2741.
6. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999 281 : 2189 2197.
7. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007 25 : 486 492.
8. Disanza A, Steffen A, Hertzog M, et al. Actin polymerization machinery: the finish line of signaling networks, the starting point of cellular movement. Cell Mol Life Sci. 2005 62 : 955 970.
9. Giretti MS, Fu X-D, De Rosa G, et al. Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS ONE. 2008 3 : e2238.
10. Louvet-Vallee S. ERM proteins: from cellular architecture to cell signaling. Biol Cell. 2000 92 : 305 316.
11. Rossy J, Gutjahr MC, Blaser N, et al. Ezrin/moesin in motile Walker 256 carcinosarcoma cells: signal-dependent relocalization and role in migration. Exp Cell Res. 2007 313 : 1106 1120.
12. Simoncini T, Scorticati C, Mannella P, et al. Estrogen receptor alpha interacts with Galpha13 to drive actin remodeling and endothelial cell migration via the RhoA/Rho kinase/moesin pathway. Mol Endocrinol. 2006 20 : 1756 1771.
13. Oshiro N, Fukata Y, Kaibuchi K. Phosphorylation of moesin by rho-associated kinase (Rho-kinase) plays a crucial role in the formation of microvilli-like structures. J Biol Chem. 1998 273 : 34663 34666.
14. Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hor-mones. Eur J Endocrinol. 2003 148 : 281 292.
15. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006 354 : 270 282.
16. Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003 2 : 205 213.
17. Bretscher A, Reczek D, Berryman M. Ezrin: a protein requiring conformational activation to link microfilaments to the plasma membrane in the assembly of cell surface structures. J Cell Sci. 1997 110 : 3011 3018.
18. Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. Cell. 2003 112 : 453 465.
19. Geiser J, Ni L, Knadler MP, et al. The population pharmacokinetics of raloxifene in post- menopausal women. Pharmaceutical Science. 1998 1 : 518.
20. Liu J, Matsuo H, Xu Q, et al. Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro. Hum Reprod. 2007 22 : 1253 1259.
21. Hibner M, Magrina JF, Lefler SR, et al. Effects of raloxifene hydrochloride on endometrial cancer cells in vitro. Gynecol Oncol. 2004 93 : 642 646.
22. Hunter KW. Ezrin, a key component in tumor metastasis. Trends Mol Med. 2004 10 : 201 204.
23. Elliott BE, Meens JA, SenGupta SK, et al. The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res. 2005 7 : R365 73.
24. Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004 10 : 182 186.
25. Hardman MJ, Emmerson E, Campbell L, et al. Selective estrogen receptor modulators accelerate cutaneous wound healing in ovariectomized female mice. Endocrinology. 2008 149 : 551 557.